Table 2:

Procedure and device characteristics

Characteristics	IPH/Subtotal^{^a}	OR	P Value
Preprocedural antiplatelet use
Yes	2.5% (17/681)	0.93 (0.27–3.23)	.91
No	2.7% (3/112)	Ref
Preprocedural platelet aggregation studies
Yes	2.5% (14/564)	0.95 (0.36–2.49)	.91
No	2.6% (6/229)	Ref
Heparin administration
Yes	2.6% (18/704)	1.14 (0.26–5.00)	.86
No	2.2% (2/89)	Ref
Reversal of heparin
Yes	5.6% (1/18)	2.33 (0.29–18.49)	.43
No	2.5% (17/689)	Ref
No. of PEDs used
1	1.7% (9/533)	Ref
2	3.3% (6/183)	1.97 (0.69–5.62)	.96
3+	6.6% (5/76)	4.10 (1.34–12.58)	.04
How multiple PEDs were used
Overlapping	1.4% (2/140)	Ref
Multiple layers	7.5% (3/40)	5.59 (0.90–34.72)	.96
Additional length	7.9% (6/76)	5.91 (1.16–30.06)	.96
Multiple layers and overlapping	0.0% (0/2)	NA
Sheaths used
Medical Arrow-Flex^{^b}
Yes	0.0% (0/35)	NA
No	3.5% (19/546)
Medical Shuttle Select
Yes	3.2% (8/249)	0.97 (0.38–2.45)	.95
No	3.3% (11/332)	Ref
Pinnacle Destination^{^c}
Yes	5.9% (2/34)	1.95 (0.43–8.80)	.39
No	3.1% (17/547)	Ref
Microcatheter used
Marksman^{^d}
Yes	3.2% (18/557)	0.77 (0.10–6.00)	.80
No	4.2% (1/24)	Ref

↵a The number of IPHs does not add up to 20 in all subanalyses because these data were missing in some patients.
↵b Teleflex, Limerick, Pennsylvania.
↵c Terumo, Tokyo, Japan.
↵d Covidien, Irvine, California.